April 2014
Reactions Weekly;Apr2014, Vol. 1497 Issue 1, p26
The article presents a case study of a 35-year-old woman with dyskinesias which developed during treatment with levodopa, followed by levodopa/benserazide for dystonia.


Related Articles

  • Amantadine/levodopa.  // Reactions Weekly;1/29/2011, Issue 1336, p6 

    The article describes the case of a 14-year-old girl who developed peak-dose dyskinesias while undergoing levodopa therapy for juvenile Parkinsonism.

  • Levodopa.  // Reactions Weekly;4/13/2013, Issue 1448, p22 

    The article presents a case study of two men who developed peak-dose levodopa-induced dyskinesias (LID) and on-off phenomena while being treated with levodopa.

  • Levodopa.  // Reactions Weekly;9/29/2012, Issue 1421, p35 

    The article describes the clinical cases of four patients, diagnosed with multiple system atrophy (MSA), who developed dyskinesias while under levodopa treatment regimen.

  • Levodopa/carbidopa.  // Reactions Weekly;10/29/2011, Issue 1375, p19 

    The article describes the case of an elderly woman diagnosed with Parkinson's disease (PD), who developed respiratory and limb/trunk dyskinesias while under levodopa/carbidopa treatment regimen.

  • Clinical Aspects and Management of Levodopa-Induced Dyskinesia. Tambasco, Nicola; Simoni, Simone; Marsili, Erica; Sacchini, Elisa; Murasecco, Donatella; Cardaioli, Gabriela; Rossi, Aroldo; Calabresi, Paolo // Parkinson's Disease (20420080);2012, p1 

    In Parkinson's disease, one of the most troublesome dilemmas is the treatment of levodopa-induced dyskinesia. After a few years, chronic treatment with levodopa is associated with the development of dyskinesias. Strategies to delay or to reduce dyskinesias are based on the change of levodopa...

  • Levodopa/carbidopa: Dyskinesia: case report.  // Reactions Weekly;6/22/2019, Vol. 1758 Issue 1, p217 

    No abstract available.

  • L-Dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations. Pearce, R. K. B.; Heikkilä, M.; Lindén, I.-B.; Jenner, P. // Psychopharmacology;2001, Vol. 156 Issue 4, p402 

    Rationale: L-Dopa induces dyskinesias during the treatment of Parkinson's disease and also in primates with nigrostriatal lesions produced by MPTP, but it is claimed that L-dopa does not provoke dyskinesia in humans or monkeys with an intact or mildly damaged nigrostriatal system. Objectives:...

  • Investigation on tolerance development to subchronic blockade of mGluR5 in models of learning, anxiety, and levodopa-induced dyskinesia in rats. Gravius, Andreas; Dekundy, Andrzej; Nagel, Jens; Morè, Lorenzo; Pietraszek, Małgorzata; Danysz, Wojciech // Journal of Neural Transmission;Dec2008, Vol. 115 Issue 12, p1609 

    In the present study, we evaluated the effects of subchronic blockade of mGluR5 by 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) on learning, anxiety and levodopa-induced dyskinesia in rats. In addition, we excluded the possibility that subchronic treatment produced pharmacokinetic...

  • Animal models of Parkinson’s disease and L-dopa induced dyskinesia: How close are we to the clinic? Lane, Emma; Dunnett, Stephen // Psychopharmacology;Aug2008, Vol. 199 Issue 3, p303 

    Several different animal models are currently used to research the neurodegenerative movement disorder Parkinson’s disease (PD). Models based on the genetic deficits associated with a small percentage of sufferers demonstrate the pathological accumulation of α-synuclein characteristic...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics